Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.
Saved in:
| Title: | Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. |
|---|---|
| Authors: | Guijosa A; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Ramirez-Gamero A; Department of Medicine, Roger Williams Medical Center, Providence, RI., Sarosiek S; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Branagan AR; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA., von Keudell G; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA., Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. |
| Source: | Blood advances [Blood Adv] 2025 Sep 23; Vol. 9 (18), pp. 4705-4715. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40674744 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Guijosa+A%22">Guijosa A</searchLink>; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ramirez-Gamero+A%22">Ramirez-Gamero A</searchLink>; Department of Medicine, Roger Williams Medical Center, Providence, RI.<br /><searchLink fieldCode="AU" term="%22Sarosiek+S%22">Sarosiek S</searchLink>; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Branagan+AR%22">Branagan AR</searchLink>; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22von+Keudell+G%22">von Keudell G</searchLink>; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Treon+SP%22">Treon SP</searchLink>; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Castillo+JJ%22">Castillo JJ</searchLink>; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Sep 23; Vol. 9 (18), pp. 4705-4715. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40674744 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1182/bloodadvances.2025016536 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4705 Titles: – TitleFull: Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Guijosa A – PersonEntity: Name: NameFull: Ramirez-Gamero A – PersonEntity: Name: NameFull: Sarosiek S – PersonEntity: Name: NameFull: Branagan AR – PersonEntity: Name: NameFull: von Keudell G – PersonEntity: Name: NameFull: Treon SP – PersonEntity: Name: NameFull: Castillo JJ IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 09 Text: 2025 Sep 23 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2473-9537 Numbering: – Type: volume Value: 9 – Type: issue Value: 18 Titles: – TitleFull: Blood advances Type: main |
| ResultId | 1 |
